JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB278601

FITC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal MEK1 phospho S218 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Immunogen corresponding to Synthetic Peptide within Human MAP2K1 phospho S218.

View Alternative Names

MEK1, PRKMK1, MAP2K1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK 1, MKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK 1

1 Images
Flow Cytometry - FITC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278601)
  • Flow Cyt

Supplier Data

Flow Cytometry - FITC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2] (AB278601)

Flow cytometric analysis of Hela cells treated with imatinib and unstained as negative control (blue) or treated with imatinib (red) or treated with pervanadate (green) and stained using ab278601.

  • Unconjugated

    Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

  • 660 APC

    APC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

  • 578 PE

    PE Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

MEK12S217S221-H2

Isotype

IgG

Light chain type

kappa

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Synthetic Peptide within Human MAP2K1 phospho S218. The exact immunogen used to generate this antibody is proprietary information.

Q02750

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "5 µL for 10^6 Cells", "FlowCyt-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Product details

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A/G
Storage buffer
Preservative: 0.09% Sodium azide Constituents: 99.71% PBS, 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MEK1 and MEK2 also known as MAP2K1 and MAP2K2 respectively are dual-specificity kinases that play roles in signaling pathways mediating cellular responses. MEK1 and MEK2 have molecular weights of approximately 45kDa. They are expressed in various tissues including the heart brain and skeletal muscles reflecting their widespread function within the organism. These proteins are often referred collectively as the MEK1/2 complex due to their shared and overlapping roles in cell signaling.
Biological function summary

MEK1 and MEK2 are integral parts of the mitogen-activated protein kinase (MAPK) signaling cascade. MEK1/2 phosphorylate and activate the ERK1/2 kinases which transmit signals from the cell surface to the nucleus regulating gene expression and cell fate decisions. The MEK1/2 proteins also act in concert with other kinases and substrates forming signaling complexes that ensure specific and regulated cellular outcomes.

Pathways

MEK1 and MEK2 play key roles within the MAPK/ERK pathway a critical signaling mechanism for cell division and survival. They also link to the RAS/MAPK pathway involved in transmitting signals from membrane receptors to the nucleus. In these pathways MEK1/2 interact with proteins like RAF kinases and ERK1/2 propagating signals that influence cellular growth and differentiation.

MEK1 and MEK2 are implicated in cancer and neurological disorders. Abnormal activity of the MEK1/2 proteins often due to mutations can lead to uncontrolled cell proliferation contributing to the development of cancers such as melanoma. In neurological disorders dysregulation of MEK1/2 signaling relates to conditions like neuro-cardio-facial-cutaneous syndromes. These proteins interact with other key players in these diseases such as mutant RAF proteins in melanoma highlighting their critical roles in disease mechanisms.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed : 29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
See full target information MAP2K1 phospho S218

Additional targets

MAP2K2 phospho S222
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
style
right-column

Associated Products

Select an associated product type
Alternative Version
Primary Antibodies

AB278759

APC Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

primary-antibodies

apc-mek1-mek2-phospho-s218-s222-antibody-mek12s217s221-h2-ab278759

0

(0 reviews)

Alternative Version
Primary Antibodies

AB278600

PE Anti-MEK1 + MEK2 (phospho S218 + S222) antibody [MEK12S217S221-H2]

primary-antibodies

pe-mek1-mek2-phospho-s218-s222-antibody-mek12s217s221-h2-ab278600

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com